BC Extra | Sep 27, 2019
Financial News

Sept. 27 Financial Quick Takes: Beam hops into IPO queue; plus Amryt, T3, Junshi, Newronika

Beam seeking NASDAQ IPO   Beam Therapeutics filed to raise up to $100 million in an IPO underwritten by J.P. Morgan, Jefferies, Barclays and Wedbush PacGrow. The base editing company has 12 preclinical programs across...
BioCentury | Sep 7, 2019
Product Development

Regeneron’s evinacumab data could make it the therapy of choice in HoFH

With a cleaner safety profile and better efficacy than marketed agents, Regeneron’s first-in-class evinacumab is poised to become the standard of care for homozygous familial hypercholesterolemia and other rare lipid disorders, including for the hardest...
BC Extra | May 21, 2019
Company News

May 21 Company Quick Takes: Verily in deal with pharmas; plus Amryt-Aegerion, Prokaryotics

Verily, pharmas partner to develop clinical programs  The Verily Life Sciences LLC of Alphabet Inc. (NASDAQ:GOOG) partnered with Novartis AG (NYSE:NVS; SIX:NOVN), Otsuka Holdings Co. Ltd. (Tokyo:4578), Pfizer Inc. (NYSE:PFE) and Sanofi (Euronext:SAN; NASDAQ:SNY) to...
BC Extra | Apr 5, 2019
Company News

Management tracks: Zealand taps Alnylam’s Dulac as CEO, plus ICER, Jnana and more

Emmanuel Dulac is leaving his post as chief international strategy officer of Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) to become the new CEO of Zealand Pharma A/S (CSE:ZEAL; NASDAQ:ZEAL), effective April 22. Dulac succeeds Adam Steensberg, the...
BioCentury | Jan 26, 2019
Product Development

Raising the BD bar

Innovator biotechs say that the business development bar has been raised for companies developing new modalities, with potential partners seeking proof of mechanism on top of proof of efficacy. A host of products based on...
BC Extra | Jun 20, 2018
Company News

Management tracks: Sanofi, NantKwest

Sanofi (Euronext:SAN; NYSE:SNY) hired Jean-Baptiste Chasseloup de Chatillon as EVP and CFO, effective Oct. 1. He was CFO and EVP at automotive company PSA Group (Euronext:UG). Natural killer cell company NantKwest Inc. (NASDAQ:NK) said Chief...
BC Extra | Oct 6, 2017
Company News

Management tracks: Impel, InGeneron

Drug delivery company Impel NeuroPharma Inc. (Seattle, Wash.) named Jon Congleton president and CEO. He was president and CEO at Nivalis Therapeutics Inc. , which merged with Alpine Immune Sciences Inc. (NASDAQ:ALPN). Regenerative medicine company InGeneron...
BC Week In Review | Sep 29, 2017
Company News

Aegerion to pay fine for Juxtapid violations

Aegerion Pharmaceuticals Inc. will pay more than $40 million to the SEC and the U.S. Department of Justice to resolve allegations associated with Juxtapid lomitapide. The drug was approved in the U.S. in 2012 as...
BC Extra | Sep 25, 2017
Company News

Aegerion to pay fine for Juxtapid violations

Aegerion Pharmaceuticals Inc. will pay more than $40 million to the SEC and the U.S. Department of Justice to resolve allegations associated with Juxtapid lomitapide. The drug was approved in the U.S. in 2012 as...
BC Extra | Apr 1, 2017
Company News

Management tracks

Immuno-oncology company Forty Seven Inc. (Palo Alto, Calif.) named Mark McCamish CEO, effective May 1. He was global head of biopharmaceutical development at the Sandoz unit of Novartis AG (NYSE:NVS; SIX:NOVN). Founding CEO Jonathan MacQuitty...
Items per page:
1 - 10 of 219
BC Extra | Sep 27, 2019
Financial News

Sept. 27 Financial Quick Takes: Beam hops into IPO queue; plus Amryt, T3, Junshi, Newronika

Beam seeking NASDAQ IPO   Beam Therapeutics filed to raise up to $100 million in an IPO underwritten by J.P. Morgan, Jefferies, Barclays and Wedbush PacGrow. The base editing company has 12 preclinical programs across...
BioCentury | Sep 7, 2019
Product Development

Regeneron’s evinacumab data could make it the therapy of choice in HoFH

With a cleaner safety profile and better efficacy than marketed agents, Regeneron’s first-in-class evinacumab is poised to become the standard of care for homozygous familial hypercholesterolemia and other rare lipid disorders, including for the hardest...
BC Extra | May 21, 2019
Company News

May 21 Company Quick Takes: Verily in deal with pharmas; plus Amryt-Aegerion, Prokaryotics

Verily, pharmas partner to develop clinical programs  The Verily Life Sciences LLC of Alphabet Inc. (NASDAQ:GOOG) partnered with Novartis AG (NYSE:NVS; SIX:NOVN), Otsuka Holdings Co. Ltd. (Tokyo:4578), Pfizer Inc. (NYSE:PFE) and Sanofi (Euronext:SAN; NASDAQ:SNY) to...
BC Extra | Apr 5, 2019
Company News

Management tracks: Zealand taps Alnylam’s Dulac as CEO, plus ICER, Jnana and more

Emmanuel Dulac is leaving his post as chief international strategy officer of Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) to become the new CEO of Zealand Pharma A/S (CSE:ZEAL; NASDAQ:ZEAL), effective April 22. Dulac succeeds Adam Steensberg, the...
BioCentury | Jan 26, 2019
Product Development

Raising the BD bar

Innovator biotechs say that the business development bar has been raised for companies developing new modalities, with potential partners seeking proof of mechanism on top of proof of efficacy. A host of products based on...
BC Extra | Jun 20, 2018
Company News

Management tracks: Sanofi, NantKwest

Sanofi (Euronext:SAN; NYSE:SNY) hired Jean-Baptiste Chasseloup de Chatillon as EVP and CFO, effective Oct. 1. He was CFO and EVP at automotive company PSA Group (Euronext:UG). Natural killer cell company NantKwest Inc. (NASDAQ:NK) said Chief...
BC Extra | Oct 6, 2017
Company News

Management tracks: Impel, InGeneron

Drug delivery company Impel NeuroPharma Inc. (Seattle, Wash.) named Jon Congleton president and CEO. He was president and CEO at Nivalis Therapeutics Inc. , which merged with Alpine Immune Sciences Inc. (NASDAQ:ALPN). Regenerative medicine company InGeneron...
BC Week In Review | Sep 29, 2017
Company News

Aegerion to pay fine for Juxtapid violations

Aegerion Pharmaceuticals Inc. will pay more than $40 million to the SEC and the U.S. Department of Justice to resolve allegations associated with Juxtapid lomitapide. The drug was approved in the U.S. in 2012 as...
BC Extra | Sep 25, 2017
Company News

Aegerion to pay fine for Juxtapid violations

Aegerion Pharmaceuticals Inc. will pay more than $40 million to the SEC and the U.S. Department of Justice to resolve allegations associated with Juxtapid lomitapide. The drug was approved in the U.S. in 2012 as...
BC Extra | Apr 1, 2017
Company News

Management tracks

Immuno-oncology company Forty Seven Inc. (Palo Alto, Calif.) named Mark McCamish CEO, effective May 1. He was global head of biopharmaceutical development at the Sandoz unit of Novartis AG (NYSE:NVS; SIX:NOVN). Founding CEO Jonathan MacQuitty...
Items per page:
1 - 10 of 219